Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

2.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
3.

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A.

Leukemia. 2019 Aug 21. doi: 10.1038/s41375-019-0548-z. [Epub ahead of print] No abstract available.

PMID:
31435023
4.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
5.

Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition.

Toubai T, Fujiwara H, Rossi C, Riwes M, Tamaki H, Zajac C, Liu C, Mathew AV, Byun J, Oravecz-Wilson K, Matsuda I, Sun Y, Peltier D, Wu J, Chen J, Seregin S, Henig I, Kim S, Brabbs S, Pennathur S, Chen G, Reddy P.

Nat Microbiol. 2019 May;4(5):800-812. doi: 10.1038/s41564-019-0373-1. Epub 2019 Mar 11.

PMID:
30858572
6.

Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.

Toubai T, Tamaki H, Peltier DC, Rossi C, Oravecz-Wilson K, Liu C, Zajac C, Wu J, Sun Y, Fujiwara H, Henig I, Kim S, Lombard DB, Reddy P.

J Immunol. 2018 Dec 1;201(11):3443-3455. doi: 10.4049/jimmunol.1800148. Epub 2018 Nov 2.

7.

Microbial metabolite sensor GPR43 controls severity of experimental GVHD.

Fujiwara H, Docampo MD, Riwes M, Peltier D, Toubai T, Henig I, Wu SJ, Kim S, Taylor A, Brabbs S, Liu C, Zajac C, Oravecz-Wilson K, Sun Y, Núñez G, Levine JE, van den Brink MRM, Ferrara JLM, Reddy P.

Nat Commun. 2018 Sep 10;9(1):3674. doi: 10.1038/s41467-018-06048-w.

8.

Murine Models of Steroid Refractory Graft-versus-Host Disease.

Toubai T, Rossi C, Tawara I, Liu C, Zajac C, Oravecz-Wilson K, Peltier D, Sun Y, Fujiwara H, Wu SR, Riwes M, Henig I, Kim S, Reddy P.

Sci Rep. 2018 Aug 20;8(1):12475. doi: 10.1038/s41598-018-30814-x.

9.

IAPs protect host target tissues from graft-versus-host disease in mice.

Toubai T, Rossi C, Oravecz-Wilson K, Liu C, Zajac C, Wu SJ, Sun Y, Fujiwara H, Tamaki H, Peltier D, Riwes M, Henig I, Brabbs S, Duckett CS, Wang S, Reddy P.

Blood Adv. 2017 Aug 16;1(19):1517-1532. doi: 10.1182/bloodadvances.2017004242. eCollection 2017 Aug 22.

10.

[HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE PERSPECTIVE OF TIME AND UP TO THE 2000 TRANSPLANT AT THE RAMBAM HEALTH CARE CAMPUS].

Henig I, Rowe J, Hadad N, Fineman R, Benyamini N, Zuckerman T.

Harefuah. 2017 Sep;156(9):589-594. Review. Hebrew.

PMID:
28971659
11.

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.

Choi SW, Braun T, Henig I, Gatza E, Magenau J, Parkin B, Pawarode A, Riwes M, Yanik G, Dinarello CA, Reddy P.

Blood. 2017 Oct 12;130(15):1760-1767. doi: 10.1182/blood-2017-06-790469. Epub 2017 Aug 7.

12.

Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.

Horowitz NA, Henig I, Henig O, Benyamini N, Vidal L, Avivi I.

Leuk Lymphoma. 2018 Mar;59(3):610-616. doi: 10.1080/10428194.2017.1347651. Epub 2017 Jul 13.

PMID:
28703077
13.

Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.

Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L, Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R.

Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30.

PMID:
28039512
14.

Nephrotic syndrome after hematopoietic stem cell transplantation: a single center experience.

Beyar Katz O, Kruzel Davila E, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Rowe JM, Ofran Y.

Minerva Med. 2015 Dec;106(6):355-7. No abstract available.

PMID:
26787650
15.

Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy.

Beyar-Katz O, Davila EK, Zuckerman T, Fineman R, Haddad N, Okasha D, Henig I, Leiba R, Rowe JM, Ofran Y.

Biol Blood Marrow Transplant. 2016 Jun;22(6):975-981. doi: 10.1016/j.bbmt.2015.12.014. Epub 2015 Dec 29. Review.

16.

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM.

Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17.

17.

JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications.

Wittmann T, Horowitz N, Benyamini N, Henig I, Zuckerman T, Rowe JM, Kra-Oz Z, Szwarcwort Cohen M, Oren I, Avivi I.

Bone Marrow Transplant. 2015 Jul;50(7):984-91. doi: 10.1038/bmt.2015.68. Epub 2015 Apr 13.

PMID:
25867649
18.

Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.

Henig I, Zuckerman T.

Rambam Maimonides Med J. 2014 Oct 29;5(4):e0028. doi: 10.5041/RMMJ.10162. eCollection 2014 Oct.

19.

Development of multifocal leukoencephalopathy in patients undergoing allogeneic stem cell transplantation-can preemptive detection of John Cunningham virus be useful?

Avivi I, Wittmann T, Henig I, Kra-Oz Z, Szwarcwort Cohen M, Zuckerman T, Horowitz NA, Benyamini N.

Int J Infect Dis. 2014 Sep;26:107-9. doi: 10.1016/j.ijid.2014.03.1381. Epub 2014 Jul 16.

20.

Novel peptides that inhibit heparanase activation of the coagulation system.

Axelman E, Henig I, Crispel Y, Attias J, Li JP, Brenner B, Vlodavsky I, Nadir Y.

Thromb Haemost. 2014 Sep 2;112(3):466-77. doi: 10.1160/TH13-12-1049. Epub 2014 Jul 17.

PMID:
25030319

Supplemental Content

Support Center